Amendments to the Claims:

Please amend claims 1 to 46 as set forth hereinafter.

Listing of Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Previously Presented) A compound of general formula (I),



wherein
R_1 is a hydroxy, aryl or amino acid group,
R_2 is hydrogen, an alkyl (C_1-C_4), a substituted alkyl (C_1-C_4) group, a dialkyl (C_1-C_4), a cyclohexyl, a phenyl or diphenyl group,
R_3 is an alkyl (C_2-C_5) group,
and/or salts thereof,
with the proviso that, if R_1 is a hydroxy group, R_2 is not a methyl group,
said compound being selected from the group comprising 4-hydroxy-1,1-dimethylproline ethyl ester iodide, 4-hydroxyproline isobutyl ester, 4-hydroxy-1,1-dimethylproline isobutyl ester iodide, 4-hydroxy-1-cyclohexylproline isobutyl ester, 4-hydroxy1-1-diphenylmethylproline isobutyl ester hydrobromide, 4-hydroxy-1-methylproline ethyl ester, 4-hydroxy-1-methylproline isobutyl ester and/or 1-methyl-4-phenylaminocarbonyloxyproline isobutyl ester, and, if R_1 is a hydroxy group, said compounds may have a methyl group in position R_2.

2. (Currently Amended) A pharmaceutical agent comprising a compound according

to ~~the preceding~~ claim 1, optionally together with conventional auxiliaries, preferably pharmaceutically acceptable carriers, adjuvants and/or vehicles.

3. (Currently Amended) The pharmaceutical agent according to ~~the preceding claim,~~
~~characterized in that~~ claim 2, wherein
the carriers are selected from the group comprising fillers, diluents, binders, humectants, disintegrants, dissolution retarders, absorption enhancers, wetting agents, adsorbents and/or lubricants.

4. (Currently Amended) The pharmaceutical agent according to ~~any of claims 2 or 3,~~
~~characterized in that~~ claim 2, wherein
the carriers are liposomes, siosomes and/or niosomes.

5. (Currently Amended) The pharmaceutical agent according to ~~any of claims 2 to 4, characterized in that~~ claim 2, wherein
the agent additionally comprises a chemotherapeutic agent.

6. (Currently Amended) The pharmaceutical agent according to ~~the preceding claim,~~
~~characterized in that~~ claim 5, wherein
the chemotherapeutic agent is selected from the group comprising oxoplatin, cis-oxoplatin, taxol, gemcitabine, vinorelbine, paclitaxel, cyclosporin and/or a combination thereof.

7. (Currently Amended) The pharmaceutical agent according to ~~any of claims 2 to 6, characterized in that~~
~~it also comprises~~ claim 2, further comprising one or more additional agents from the group of antiviral, antimycotic, antibacterial and/or immunostimulatory agents.

8. (Cancelled)

9. (Currently Amended) ~~Use of~~ Method for the diagnosis, prophylaxis, follow-up, therapy, and/or aftercare of a disease associated with cell growth, cell differentiation and/or cell division, comprising
administering to a person in need thereof and/or benefiting therefrom 4-hydroxyproline ethyl ester, 4-hydroxy-1,1-dimethylproline ethyl ester iodide, 4-hydroxyproline isobutyl ester, 4-hydroxy-1,1-dimethylproline isobutyl ester iodide, 4-hydroxy-1-cyclohexylproline isobutyl ester, 4-hydroxy-1-diphenylmethylproline isobutyl ester hydrobromide, 4-hydroxy-1-methylproline, 4-hydroxy-1-methylproline ethyl ester, 4-hydroxy-1-methylproline isobutyl ester, 1-methyl-4-phenylaminocarbonyloxyproline, 1-methyl-4-phenylaminocarbonyloxyproline isobutyl ester, (R)-(+)-α,α-diphenyl-2-pyrrolidinemethanol and/or (S)-(-)-α,α-diphenyl-2-pyrrolidinemethanol and/or derivatives, metabolites, enantiomers and/or isomers thereof in ~~the~~ a diagnosis, prophylaxis, follow-up, therapy, and/or aftercare of diseases associated with cell growth, cell differentiation and/or cell division effective amount, wherein said disease ~~being~~ is a tumor.

10. (Currently Amended) The ~~use according to preceding claim, characterized in that~~ method of claim 9, wherein
the tumor disease is ~~diseases are selected from the group of~~ a neoplastic ~~tumors~~ tumor, an inflammatory ~~tumors~~ tumor, ~~abscesses, effusions and/or edemas~~ an abscess, effusion and/or edema.

11. (Currently Amended) The ~~use according to the preceding claim, characterized in that~~ method of claim 9, wherein
the tumor is a solid tumor or a leukemia.

12. (Currently Amended) The ~~use according to the preceding claim, characterized in that~~ method of claim 11, wherein
the solid tumor is a tumor of the urogenital tract and/or gastrointestinal tract.

13. (Currently Amended) The ~~use according to any of claims 8 to 12, characterized in that~~ method of claim 9, wherein
the tumor is a colon carcinoma, stomach carcinoma, pancreas carcinoma, small intestine carcinoma, ovarian carcinoma, cervical carcinoma, lung carcinoma, prostate carcinoma, mammary carcinoma, renal cell carcinoma, a brain tumor, head-throat tumor, liver carcinoma, and/or a metastase of the above tumors.

14. (Currently Amended) The ~~use according to any of claims 8 to 13, characterized in that~~ method of claim 11, wherein
the solid tumor is a mammary, bronchial, colorectal, and/or prostate carcinoma and/or a metastase of the above tumors.

15. (Currently Amended) The ~~use according to any of claims 8 to 14, characterized in that~~ method of claim 12, wherein
the tumor of the urogenital tract is a bladder carcinoma and/or a metastase of such tumors.

16. (Currently Amended) The ~~use according to any of claims 8 to 15, characterized in that~~ method of claim 9, wherein
said follow-up is monitoring the effectiveness of an anti-tumor treatment.

17. (Currently Amended) ~~The use according to any of claims 8 to 16, characterized in that~~ A method for the prophylaxis, prevention, diagnosis, attenuation, therapy, follow-up and/or aftercare of metastasizing, invasion, infiltration, tumor growth and/or angiogenesis comprising
administering to a person in need thereof and/or benefiting therefrom
at least one ~~compound according to claim 1 and/or a~~ pharmaceutical agent according to ~~any of claims 2 to 7 are employed in the~~ claim 2 in a prophylaxis, prevention, diagnosis, attenuation, therapy, follow-up and/or aftercare of metastasizing, invasion, infiltration, tumor growth and/or angiogenesis effective amount.

18. (Currently Amended) The ~~use according to any of claims 8 to 17, characterized in that~~ method of claim 17, wherein
said follow-up is monitoring the effectiveness of an anti-tumor treatment.

19. (Currently Amended) The ~~use according to any of claims 8 to 18, characterized in that~~
~~at least one compound according to claim 1 and/or a pharmaceutical agent according to any of claims 2 to 7 are employed in~~ method of claim 17, wherein the methods are used as part of a combined therapy.

20. (Currently Amended) The ~~use according to the preceding claim, characterized in that~~
~~said~~ combined therapy ~~comprises~~ of claim 19 further comprising a chemotherapy, a treatment with cytostatic agents and/or a radiotherapy.

21. (Currently Amended) The ~~use according to the preceding claim, characterized in that~~
~~the~~ combined therapy of claim 19 further comprising ~~comprises~~ an adjuvant, biologically specified form of therapy.

22. (Currently Amended) The ~~use according to the preceding claim, characterized in that~~ method of claim 21, wherein
said form of therapy is an immune therapy.

23. (Currently Amended) The ~~use according to any of claims 8 to 22 to increase the~~ method of claim 17, wherein said method increases sensitivity of tumor cells to cytostatic agents and/or radiation.

24. (Currently Amended) The ~~use according to any of claims 8 to 23 for inhibiting the~~ method of claim 17, wherein said method inhibits viability, ~~the~~ proliferation rate of cells in order to induce apoptosis and/or cell cycle arrest.

25. (Currently Amended) The ~~use according to any of claims 8 to 24, characterized in that~~
~~at least one compound according to claim 1 and/or a pharmaceutical agent according to any of claims 2 to 7 are prepared as~~ pharmaceutical agent of claim 2, wherein said agent is in form of a gel, poudrage, powder, tablet, sustained-release tablet, premix, emulsion, brew-up formulation, drops, concentrate, granulate, syrup, pellet, bolus, capsule, aerosol, spray and/or inhalant and/or inhalant ~~and applied in this form~~.

26. (Currently Amended) The ~~use according to the preceding claim, characterized in that~~
~~at least one compound according to claim 1 and/or a pharmaceutical agent according to any of claims 2 to 7 are present~~ pharmaceutical agent of claim 2, wherein said agent is present in a preparation at a concentration of from 0.1 to 99.5, preferably from 0.5 to 95.0, and more preferably from 20.0 to 80.0 weight percent.

27. (Currently Amended) The ~~use according to the preceding claim, characterized in that~~ pharmaceutical agent of claim 26, wherein
the preparation is employed orally, subcutaneously, intravenously, intramuscularly, intraperitoneally and/or topically.

28. (Currently Amended) The ~~use according to any of claims 8 to 27, characterized in that~~
~~at least one compound according to claim 1 and/or a~~ method of claim 17, wherein the pharmaceutical agent ~~according to any of claims 2 to 7 are~~ is employed in overall amounts of more than 0.1 ~~g per kg~~ mg per kg body weight per 24 hours.

29. (Currently Amended) The ~~use according to any of claims 8 to 28, characterized in that~~
~~at least one compound according to claim 1 and/or a~~ method of claim 28,

wherein the pharmaceutical agent ~~according to any of claims 2 to 7 are~~ is employed in overall amounts of 0.05 to 500 ~~g per kg~~ mg per kg, preferably 5 to 100 ~~g per kg~~ mg per kg body weight per 24 hours.

30. (Currently Amended) A method for the treatment of a tumor disease, ~~characterized in that~~ comprising contacting
an organism is contacted with an effective amount of a compound according to claim 1 ~~and/or a pharmaceutical agent according to any of claims 2 to 7~~.

31. (Currently Amended) ~~Use of the~~ A method for the inhibiting collagen IV and/or glutathione S transferase (GST) comprising administering to a cell or person benefiting from such inhibition a compound according to claim 1 ~~and/or the pharmaceutical agent according to any of claims 2 to 7 for inhibiting~~ in an collagen IV and/or glutathione S transferase (GST) inhibiting amount.

32. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
1-methyl-4-phenylaminocarbonyloxyproline ethyl ester is obtained by reacting 4-hydroxy-1-methylproline ethyl ester and phenyl isocyanate in acetonitrile.

33. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
1-methyl-4-phenylaminocarbonyloxyproline isobutyl ester is obtained by reacting 4-hydroxy-1-methylproline isobutyl ester and phenyl isocyanate in acetonitrile.

34. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
4-hydroxy-1-methylproline is obtained by reacting 4-hydroxyproline in formalin with Pd/C in a hydrogenation apparatus.

35. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
4-hydroxy-1-methylproline ethyl ester is obtained by reacting 4-hydroxyproline ethyl ester and formalin in ethanol.

36. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
4-hydroxy-1-methylproline isobutyl ester is obtained by reacting formalin, Pd/C and ethanol and 4-hydroxyproline isobutyl ester.

37. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
4-hydroxy-1-methylproline isobutyl ester is obtained by reacting formalin and 4-hydroxyproline isobutyl ester in the presence of Pd/C in ethanol.

38. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
cis-4-hydroxy-L-proline ethyl ester is obtained by contacting 4-hydroxyproline with HCl in ethanol.

39. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
cis-4-hydroxy-L-proline isobutyl ester is obtained by reacting 4-hydroxyproline in isobutanol.

40. (Currently Amended) A method for the preparation of a compound according to

claim 1,
~~characterized in that~~ wherein
4-hydroxy-1,1-dimethylproline ethyl ester iodide is obtained by reacting hydroxyproline ethyl ester in acetonitrile, methyl iodide and triethylamine.

41. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
4-hydroxy-1,1-dimethylproline isobutyl ester iodide is obtained by reacting 4-hydroxyproline isobutyl ester and methyl iodide in triethylamine and acetonitrile.

42. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
4-hydroxy-1-alkylproline ester bromide is obtained by suspending 4-hydroxyproline ester in acetonitrile and contacting with the corresponding alkyl bromide in the presence of ether.

43. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
4-hydroxy-1-cyclohexylproline isobutyl ester is obtained by dissolving the corresponding hydrobromide in chloroform and contacting with gaseous ammonia.

44. (Currently Amended) A method for the preparation of a compound according to claim 1,
~~characterized in that~~ wherein
4-hydroxy-1-diphenylmethylproline isobutyl ester hydrobromide is obtained by contacting 4-hydroxyproline isobutyl ester, methyl iodide, triethylamine in acetonitrile.

45. (Currently Amended) A kit comprising at least one compound according to claim 1 ~~and/or a pharmaceutical agent according to any of claims 2 to 7~~, optionally together with information for combining the contents of the kit.

46. (Cancelled)